ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

SURVEY: Cognitive Impairment II

Top 3 Nutrients to Detox the Liver and Soothe Digestion

Natural Bladder Control, Go Less and Live More

Study bodes well for low-carb eaters

Top Vitamin and Mineral Deficiencies — Are You at Risk?

Vital Molecule Increases Cellular Energy and Improves Cognitive Function

Omega Fix for Obesity: How the Right Fats Fight Fat

Potential of Quercetin in the Treatment of Melanoma

How Pomegranate May Protect Against Cancer

Trimming the spare tire: Canola oil may cut belly fat

 
Print Page
Email Article

Study Demonstrates that Low Dose Tamoxifen May Be Effective in Treating Breast Cancer

  [ 153 votes ]   [ Discuss This Article ]
www.ProHealth.com • April 8, 2003


Lower dose regimen associated with fewer side effects - May enhance treatment compliance

Philadelphia, PA – Administering tamoxifen at lower doses than the current standard dose appears to effectively reduce breast cancer proliferation while causing fewer side effects, according to data published in the Proceedings for the 2003 Annual Meeting of the American Association for Cancer Research (AACR).

Unlike standard chemotherapy, estrogen-based agents such as tamoxifen work by saturating the estrogen receptor. Once saturation occurs, there is no longer any treatment benefit regardless of regimen frequency or dosing, and additional drug may cause an increase in side effects.

"This study demonstrates that tamoxifen doses as low as one milligram per day maintain clinical effect against the treatment of breast cancer," said Andrea Decensi, M.D., Director of the Division of Cancer Prevention, European Institute of Oncology, Milan, Italy. "Since lower tamoxifen doses may also reduce the risks of potential serious side effects such as endometrial cancer, this study concludes that more drug may not be necessarily better."

The study protocol randomized 120 women with estrogen receptor (ER)-positive breast cancer toeither one, five or 20 milligrams (mg) of tamoxifen daily for four weeks prior to surgery. Results in these women were compared with two non-randomized control groups – one of 34 women with ER-negative breast cancer who were recruited concurrently during the trial, and one of 29 women with ER-positive breast cancer who were recruited after randomization was complete.

Changes in Ki-67 (the key identifying marker that measures tumor proliferation and which is associated with tumor shrinkage and prognosis in breast cancer) were measured in cancer tissue before and after tamoxifen treatment. Tamoxifen significantly reduced Ki-67 (p<0.001) but there was no dose response (p=0.81). All three doses reduced Ki-67 levels equally. Although more drug was measured in the tumor at the 20 mg dose, there was no correlation to increased Ki-67 reduction.

"Tamoxifen is the most widely prescribed agent in the world for the prevention and treatment of breast cancer," said Dr. Decensi. "Although tamoxifen has been studied since the 1970s, we have yet to determine the optimal biologic dose."

While there may be potential benefits to lower doses of drug in terms of cancer prevention, the study identified other disease markers that were dose-dependent, specifically circulating biomarkers reflecting drug estrogenicity such as insulin-like growth factor-I, cholesterol, triglycerides and antithrombin-III. Lower doses of tamoxifen might therefore reduce its preventative effects in cardiovascular disease and osteoporosis, but also reduce important adverse events such as venous thrombosis. There was also a direct link to the decreased reduction of cholesterol and low dose tamoxifen.

Breast cancer is the second-leading cause of cancer-related death in women. According to the American Cancer Society, in 2003 more than 266,000 women and 1,300 men will be diagnosed with breast cancer and more than 39,000 women and 400 men will die from the disease.


Founded in 1907, the American Association for Cancer Research (AACR) is a professional society of more than 20,000 laboratory and clinical scientists engaged in cancer research in the United States and more than 60 other countries. AACR's mission is to accelerate the prevention and cure of cancer through research, education, communication and advocacy. Its principal activities include the publication of five major peer-reviewed scientific journals (Cancer Research; Clinical Cancer Research; Molecular Cancer Therapeutics; Molecular Cancer Research; and Cancer Epidemiology, Biomarkers & Prevention). AACR's annual meeting attracts more than 12,000 participants who share new and significant discoveries in the cancer field, and the AACR's specialty meetings throughout the year focus on all the important areas of basic, translational and clinical cancer research.



Post a Comment

Featured Products From the ProHealth Store
Energy NADH™ 12.5mg Ultra EPA  - Fish Oil Mitochondria Ignite™ with NT Factor®


Article Comments



Be the first to comment on this article!

Post a Comment


 
Natural Pain Relief Supplements

Featured Products

Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium
Vitamin D3 Extreme™ Vitamin D3 Extreme™
50,000 IU Vitamin D3 - Prescription Strength
Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils
FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid
Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%

Natural Remedies

How to Jump-start and Sustain Energy Production in CFS How to Jump-start and Sustain Energy Production in CFS
Vitamin K-2 – A Key Player in Cardiovascular and Bone Health Vitamin K-2 – A Key Player in Cardiovascular and Bone Health
Fatigue & Fibro Fog: Could You Have a B-12 Deficiency? Fatigue & Fibro Fog: Could You Have a B-12 Deficiency?
The Revolutionary 'Good Fat' That Promotes Heart, Brain, Bone and Joint Health The Revolutionary 'Good Fat' That Promotes Heart, Brain, Bone and Joint Health
Research Links Green Tea to Weight Loss Research Links Green Tea to Weight Loss

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE TO OUR NEWSLETTERS
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2016 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map